Does celecoxib with sodium valproate have an augmentation effect on acute mania in bipolar disorder? A double-blind controlled clinical trial in Iran.
Journal
International clinical psychopharmacology
ISSN: 1473-5857
Titre abrégé: Int Clin Psychopharmacol
Pays: England
ID NLM: 8609061
Informations de publication
Date de publication:
01 09 2023
01 09 2023
Historique:
medline:
9
8
2023
pubmed:
9
5
2023
entrez:
9
5
2023
Statut:
ppublish
Résumé
Inflammatory processes in the brain play a role in acute mania etiopathogenesis. There is little evidence indicating the efficacy of celecoxib adjuvant therapy in treatmenting of manic episodes of bipolar disorder. Therefore, this clinical trial aimed to assess the celecoxib effect on treating acute mania. In a double-blind, placebo-controlled trial, 58 patients meeting the criteria for acute mania were enrolled. After considering eligibility, 45 patients were included in the study and randomly divided into two groups. The first group (23 patients) received sodium valproate 400 mg/day along with celecoxib 400 mg/day, and the second group (22 patients) received sodium valproate 400 mg/day and a placebo. The subjects were evaluated by the Young Mania Rating Scale (YMRS) at the beginning of the study and 9, 18, and 28 days following the initiation of the medication. Evaluation of baseline factors indicated a significant difference in age ( P = 0.01) and psychiatric history ( P = 0.02) between the two groups. However, other factors were similar between groups ( P ≥ 0.05). Comparing the YMRS score between celecoxib and placebo groups revealed no significant difference on days 0, 9, 18, and 28. However, the YMRS score at the end of the study decreased by 16.05 ± 7.65 in the intervention group ( P < 0.001) and 12.50 ± 5.98 in controls ( P < 0.001) compared to the baseline, the trend of change was not significant between the two groups during the time of the study ( F = 0.38; P = 0.84). Although celecoxib adjuvant therapy indicated no considerable side effects, a longer treatment duration may be needed to detect its beneficial effects for treating acute mania in bipolar patients. Trial registration: Iran clinical trial register: IRCT20200306046708N1.
Identifiants
pubmed: 37159172
doi: 10.1097/YIC.0000000000000454
pii: 00004850-990000000-00061
doi:
Substances chimiques
Valproic Acid
614OI1Z5WI
Celecoxib
JCX84Q7J1L
Antipsychotic Agents
0
Banques de données
IRCT
['IRCT20200306046708N1']
Types de publication
Randomized Controlled Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
336-341Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Références
Arabzadeh S, Ameli N, Zeinoddini A, Rezaei F, Farokhnia M, Mohammadinejad P, et al. (2015). Celecoxib adjunctive therapy for acute bipolar mania: a randomized, double-blind, placebo-controlled trial. Bipolar Disord 17:606–614.
Association, W. M (2001). World Medical Association Declaration of Helsinki. Ethical principles for medical research involving human subjects. Bull World Health Organ 79:373.
Azad FJ, Talaei A, Rafatpanah H, Yousefzadeh H, Jafari R, Talaei A, et al. (2014). Association between cytokine production and disease severity in Alzheimer’s disease. Iran J Allergy Asthma Immunol 13:433–439.
Bavaresco DV, Colonetti T, Grande AJ, Colom F, Valvassori SS, Quevedo J, et al. (2019). Efficacy of celecoxib adjunct treatment on bipolar disorder: systematic review and meta-analysis. CNS Neurol Disord Drug Targets 18:19–28.
Becking K, Boschloo L, Vogelzangs N, Haarman B, Riemersma-Van Der Lek R, Penninx B, et al. (2013). The association between immune activation and manic symptoms in patients with a depressive disorder. Transl Psychiatry 3:e314.
Bosetti F, Rintala J, Seemann R, Rosenberger T, Contreras M, Rapoport S, et al. (2002). Chronic lithium downregulates cyclooxygenase-2 activity and prostaglandin E 2 concentration in rat brain. Mol Psychiatry 7:845–850.
Bosetti F, Weerasinghe GR, Rosenberger TA, Rapoport SI (2003). Valproic acid down-regulates the conversion of arachidonic acid to eicosanoids via cyclooxygenase-1 and-2 in rat brain. J Neurochem 85:690–696.
Brietzke E, Scheinberg M, lafer B (2011). Therapeutic potential of interleukin-6 antagonism in bipolar disorder. Med Hypotheses 76:21–23.
Cerimele JM, Chwastiak LA, Dodson S, Katon WJ (2014). The prevalence of bipolar disorder in general primary care samples: a systematic review. Gen Hosp Psychiatry 36:19–25.
Dickerson F, Stallings C, Origoni A, Vaughan C, Katsafanas E, Khushalani S, et al. (2013). A combined marker of inflammation in individuals with mania. PLoS One 8:e73520.
Dols A, Sienaert P, van Gerven H, Schouws S, Stevens A, Kupka R, et al. (2013). The prevalence and management of side effects of lithium and anticonvulsants as mood stabilizers in bipolar disorder from a clinical perspective: a review. Int Clin Psychopharmacol 28:287–296.
Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK, et al. (2010). A meta-analysis of cytokines in major depression. Biol Psychiatry 67:446–457.
Ghelardoni S, Tomita YA, Bell JM, Rapoport SI, Bosetti F (2004). Chronic carbamazepine selectively downregulates cytosolic phospholipase A 2 expression and cyclooxygenase activity in rat brain. Biol Psychiatry 56:248–254.
Gitlin M (2006). Treatment-resistant bipolar disorder. Mol Psychiatry 11:227–240.
Hamdani N, Tamouza R, Leboyer M (2011). Immuno-inflammatory markers of bipolar disorder: a review of evidence. Front Biosci (Elite edition) 4:2170–2182.
Hamdani N, Doukhan R, Kurtlucan O, Tamouza R, Leboyer M (2013). Immunity, inflammation, and bipolar disorder: diagnostic and therapeutic implications. Curr Psychiatry Rep 15:1–8.
Kaplan BJ (2016). Kaplan and Sadock’s synopsis of psychiatry. Behavioral sciences/clinical psychiatry. Tijdschr Psychiatr 58:78–79.
Kargar M, Yoosefi A, Akhondzadeh S, Artonian V, Ashouri A, Ghaeli P (2015). Effect of adjunctive celecoxib on BDNF in manic patients undergoing electroconvulsive therapy: a randomized double blind controlled trial. Pharmacopsychiatry 48:268–273.
Leboyer M, Soreca I, Scott J, Frye M, Henry C, Tamouza R, et al. (2012). Can bipolar disorder be viewed as a multi-system inflammatory disease? J Affect Disord 141:1–10.
Marazziti D, Mucci F, Fontenelle LF (2018). Immune system and obsessive-compulsive disorder. Psychoneuroendocrinology 93:39–44.
Mcnamara RK, Lotrich FE (2012). Elevated immune-inflammatory signaling in mood disorders: a new therapeutic target? Expert Rev Neurother 12:1143–1161.
Merikangas KR, Jin R, He J-P, Kessler RC, Lee S, Sampson NA, et al. (2011). Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative. Arch Gen Psychiatry 68:241–251.
Middleton R, Wheaton MG, Kayser R, Simpson HB (2019). Treatment resistance in obsessive-compulsive disorder. In: Kim YK. Treatment resistance in psychiatry. Springer. pp. 165–177.
Modabbernia A, Taslimi S, Brietzke E, Ashrafi M (2013). Cytokine alterations in bipolar disorder: a meta-analysis of 30 studies. Biol Psychiatry 74:15–25.
Mousavi SY, Khezri R, Karkhaneh-Yousefi MA, Mohammadinejad P, Gholamian F, Mohammadi MR, et al. (2017). A randomized, double-blind placebo-controlled trial on effectiveness and safety of celecoxib adjunctive therapy in adolescents with acute bipolar mania. J Child Adolesc Psychopharmacol 27:494–500.
Müller N, Myint A-M, Schwarz MJ (2011). Inflammatory biomarkers and depression. Neurotox Res 19:308–318.
Müller N, Myint A-M, Schwarz MJ (2012). Inflammation in schizophrenia. Adv Protein Chem Struct Biol 88:49–68.
Ong H, Ong L, Tan T, Chean K (2013). Cardiovascular effects of common analgesics. Med J Malaysia 68:189–194.
Rapoport SI, Basselin M, Kim H-W, Rao JS (2009). Bipolar disorder and mechanisms of action of mood stabilizers. Brain Res Rev 61:185–209.
Shahini N, Talaei A, Shalbafan M, Faridhosseini F, Ziae M (2021). Efficacy of the addition of celecoxib to selective serotonin reuptake inhibitors in treating obsessive–compulsive disorder: a double-blind clinical trial study. Basic Clin Neurosci 12:489–498.
Vancampfort D, Vansteelandt K, Correll CU, Mitchell AJ, De Herdt A, Sienaert P, et al. (2013). Metabolic syndrome and metabolic abnormalities in bipolar disorder: a meta-analysis of prevalence rates and moderators. Am J Psychiatry 170:265–274.